Preliminary Phase II Results of Selinexor (KPT-‐330), an Oral Selective Inhibitor of Nuclear Export, in Patients with Heavily Pretreated Gynecological Cancers
Preliminary Phase II Results of Selinexor (KPT-‐330), an Oral Selective Inhibitor of Nuclear Export, in Patients with Heavily Pretreated Gynecological Cancers